Some studies have highlighted the role of Janus kinase 3 (JAK3) in the development of various cancers. To manage this condition, inhibitors such as decernotinib and facitinib are commonly used, although these drugs can cause elevations in liver enzymes and increased lipid levels. It is essential to recognize that new therapies are being developed to inhibit cancer cell growth, using both theoretical and experimental approaches. This study aimed to investigate whether carbazole derivatives (1-25) could interact with JAK3, using the 3pjc protein, decernotinib, and facitinib as reference compounds in the DockingServer tool. The results showed that the carbazole analogs engage with different regions of the 3pjc protein compared to facitinib and decernotinib. Additionally, the inhibition constant (Ki) for carbazole-protein interactions with compounds 2, 5, 9, 17, 18, and 22 was lower than that of the reference drugs, suggesting that these carbazole analogs could be effective JAK3 inhibitors and may help reduce cancer cell growth.
Publication System